Exelixis

Originally published March 25.
The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.

Originally published Dec. 23.
EU's CHMP Issues Positive Opinion Exelixis' Cometriq for Medullary Thyroid Cancer

A team led by investigators at Cedars-Sinai Medical Center and the University of California, Los Angeles has developed a new approach for analyzing circulating tumor cells obtained from prostate cancer patients using chip- and sequencing-based applications.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

Around the Regions

Premium

Gaithersburg West Master Plan, Ben Franklin Technology Partners, University of Houston Institute of Biomedical Research, Connecticut Economic Development Consolidations, South San Francisco Life Sciences Career Fair, New York City Biotechnology Tax Credit

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.